Recent clinical development of sEH inhibitors (sEHIs) has targeted various inflammation-associated diseases such as hypertension, diabetic neuropathy, and chronic obstructive pulmonary disease (COPD) (27, 41, 42, 57). This evidence concerns the gene EPHX2 and chronic obstructive pulmonary disease.